动脉粥样硬化性心血管疾病分层管理下的血脂干预措施新进展
New Advances in Lipid Interventions under Stratified Management of Atherosclerotic Cardiovascular Disease
DOI: 10.12677/acm.2024.1451662, PDF,   
作者: 张卓然：新疆医科大学第一附属医院心脏中心，新疆 乌鲁木齐；新疆医科大学第一临床医学院，新疆 乌鲁木齐；杨毅宁*：新疆医科大学第一附属医院心脏中心，新疆 乌鲁木齐；新疆维吾尔自治区人民医院心内科，新疆 乌鲁木齐
关键词: 动脉粥样硬化性心血管疾病；血脂管理；一级预防；二级预防；Atherosclerotic Cardiovascular Disease； Lipid Management； Primary Prevention； Secondary Prevention
摘要: 动脉粥样硬化性心血管疾病(ASCVD)是全球范围内危害最大，疾病负担最重的慢性病类型之一。为积极控制ASCVD疾病危害，2023年我国更新了血脂管理指南，其中详述了最新的ASCVD风险评估方案以及对于不同ASCVD风险分层人群的血脂管理靶标和干预措施建议。本文将结合中国血脂管理指南(2023年)的建议，浅析近年来各类血脂干预措施的新进展。
Abstract: Atherosclerotic cardiovascular disease (ASCVD) is one of the most harmful chronic diseases with the highest burden worldwide. In order to actively control the risk of ASCVD, China’s lipid management guidelines were updated in 2023, which detailed the latest ASCVD risk stratification as well as the recommendations of lipid management targets and interventions for different ASCVD risk populations. In this article, we will describe the new advances in various lipid interventions in recent years, taking into account the recommendations of the Chinese Guidelines for Lipid Management (2023).
文章引用：张卓然, 杨毅宁. 动脉粥样硬化性心血管疾病分层管理下的血脂干预措施新进展[J]. 临床医学进展, 2024, 14(5): 2150-2156. https://doi.org/10.12677/acm.2024.1451662

参考文献

[1] 中国心血管健康与疾病报告编写委员会. 中国心血管健康与疾病报告2022概要[J]. 心脑血管病防治, 2023, 23(7): 1-19 24.
[2] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
[3] 国家卫生健康委员会. 中国居民营养与慢性病状况报告(2020年) [J]. 营养学报, 2020, 42(6): 521.
[4] Estruch, R. (2010) Anti-Inflammatory Effects of the Mediterranean Diet: The Experience of the PREDIMED Study. Proceedings of the Nutrition Society, 69, 333-340. [Google Scholar] [CrossRef] 
[5] Wang, Y., Feng, L., Zeng, G., et al. (2022) Effects of Cuisine-Based Chinese Heart-Healthy Diet in Lowering Blood Pressure among Adults in China: Multicenter, Single-Blind, Randomized, Parallel Controlled Feeding Trial. Circulation, 146, 303-315. [Google Scholar] [CrossRef] 
[6] Oktay, A.A., Lavie, C.J., Kokkinos, P.F., et al. (2017) The Interaction of Cardiorespiratory Fitness with Obesity and the Obesity Paradox in Cardiovascular Disease. Progress in Cardiovascular Diseases, 60, 30-44. [Google Scholar] [CrossRef] [PubMed]
[7] Fiuza-Luces, C., Santos-Lozano, A., Joyner, M., et al. (2018) Exercise Benefits in Cardiovascular Disease: Beyond Attenuation of Traditional Risk Factors. Nature Reviews Cardiology, 15, 731-743. [Google Scholar] [CrossRef] [PubMed]
[8] Melov, S., Tarnopolsky, M.A., Beckman, K., et al. (2007) Resistance Exercise Reverses Aging in Human Skeletal Muscle. PLOS ONE, 2, e465. [Google Scholar] [CrossRef] [PubMed]
[9] Young, D.R., Hivert, M.-F., Alhassan, S., et al. (2016) Sedentary Behavior and Cardiovascular Morbidity and Mortality: A Science Advisory from the American Heart Association. Circulation, 134, e262-e279. [Google Scholar] [CrossRef] 
[10] Baigent, C., Blackwell, L., Emberson, J., et al. (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. The Lancet, 376, 1670-1681. [Google Scholar] [CrossRef] 
[11] Ridker, P.M., Mora, S. and Rose, L. (2016) Percent Reduction in LDL Cholesterol Following High-Intensity Statin Therapy: Potential Implications for Guidelines and for the Prescription of Emerging Lipid-Lowering Agents. European Heart Journal, 37, 1373-1379. [Google Scholar] [CrossRef] [PubMed]
[12] 血脂康调整血脂对冠心病二级预防研究协作组. 中国冠心病二级预防研究[J]. 中华心血管病杂志, 2005, 33(2): 109-115.
[13] Liao, J., Wang, X., Li, Z. and Ouyang, D. (2021) Pharmacokinetic Study of Oral 14C-Radiolabeled Hyzetimibe, a New Cholesterol Absorption Inhibitor. Frontiers in Pharmacology, 12, Article 665372. [Google Scholar] [CrossRef] [PubMed]
[14] 韩雅玲, 马颖艳, 苏国海, 等. 阿利西尤单抗与依折麦布治疗高胆固醇血症合并心血管高危患者的疗效及安全性比较: ODYSSEY EAST研究中国地区亚组分析[J]. 中华心血管病杂志, 2020, 48(7): 593-599.
[15] Thedrez, A., Blom, D.J., Ramin-Mangata, S., et al. (2018) Homozygous Familial Hypercholesterolemia Patients with Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, 592-598. [Google Scholar] [CrossRef] 
[16] Chen, Y., Yuan, Z., Lu, J., et al. (2019) Randomized Study of Evolocumab in Patients with Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the Chinese Population from the BERSON Clinical Trial. Diabetes, Obesity and Metabolism, 21, 1464-1473. [Google Scholar] [CrossRef] [PubMed]
[17] 国家老年医学中心, 中国医药教育协会老年药学专业委员会, 中国药学会医院药学专业委员会, 等. 小干扰RNA降脂药物药学专家共识[J]. 中国医院药学杂志, 2024, 44(1): 9-17.
[18] Ray, K.K., Bays, H.E., Catapano, A.L., et al. (2019) Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. The New England Journal of Medicine, 380, 1022-1032. [Google Scholar] [CrossRef] 
[19] Nissen, S.E., Lincoff, A.M., Brennan, D., et al. (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New England Journal of Medicine, 388, 1353-1364. [Google Scholar] [CrossRef] 
[20] Raal, F.J., Rosenson, R.S., Reeskamp, L.F., et al. (2020) Evinacumab for Homozygous Familial Hypercholesterolemia. The New England Journal of Medicine, 383, 711-720. [Google Scholar] [CrossRef] 
[21] Markham, A. (2021) Evinacumab: First Approval. Drugs, 81, 1101-1105. [Google Scholar] [CrossRef] [PubMed]
[22] Rosenson, R.S., Burgess, L.J., Ebenbichler, C.F., et al. (2020) Evinacumab in Patients with Refractory Hypercholesterolemia. The New England Journal of Medicine, 383, 2307-2319. [Google Scholar] [CrossRef] 
[23] Hamada, M. and Farzam, K. (2024) Mipomersen. StatPearls, Treasure Island.
[24] Laufs, U., Parhofer, K.G., Ginsberg, H.N., et al. (2020) Clinical Review on Triglycerides. European Heart Journal, 41, 99-109. [Google Scholar] [CrossRef] [PubMed]
[25] Zomer, E., Gurusamy, K., Leach, R., et al. (2016) Interventions that Cause Weight Loss and the Impact on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis. Obesity Reviews, 17, 1001-1011. [Google Scholar] [CrossRef] [PubMed]
[26] Appel, L.J., Sacks, F.M., Carey, V.J., et al. (2005) Effects of Protein, Monounsaturated Fat, and Carbohydrate Intake on Blood Pressure and Serum Lipids: Results of the OmniHeart Randomized Trial. JAMA, 294, 2455-2464. [Google Scholar] [CrossRef] [PubMed]
[27] Boden, W.E., Probstfield, J.L., Anderson, T., et al. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267. [Google Scholar] [CrossRef] 
[28] Katsiki, N., Nikolic, D., Montalto, G., et al. (2013) The Role of Fibrate Treatment in Dyslipidemia: An Overview. Current Pharmaceutical Design, 19, 3124-3131. [Google Scholar] [CrossRef] [PubMed]
[29] Manson, J.E., Cook, N.R., Lee, I.-M., et al. (2019) Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. The New England Journal of Medicine, 380, 23-32. [Google Scholar] [CrossRef] 
[30] Yokoyama, M., Origasa, H., Matsuzaki, M., et al. (2007) Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): A Randomised Open-Label, Blinded Endpoint Analysis. The Lancet, 369, 1090-1098. [Google Scholar] [CrossRef] 
[31] Bhatt, D.L., Steg, P.G., Miller, M., et al. (2019) Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine, 380, 11-22. [Google Scholar] [CrossRef] 
[32] Araki, E., Yamashita, S., Arai, H., et al. (2018) Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients with Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 41, 538-546. [Google Scholar] [CrossRef] [PubMed]
[33] Brahm, A.J. and Hegele, R.A. (2016) Lomitapide for the Treatment of Hypertriglyceridemia. Expert Opinion on Investigational Drugs, 25, 1457-1463. [Google Scholar] [CrossRef] [PubMed]
[34] Sacks, F.M., Stanesa, M. and Hegele, R.A. (2014) Severe Hypertriglyceridemia with Pancreatitis: Thirteen Years’ Treatment with Lomitapide. JAMA Internal Medicine, 174, 443-447. [Google Scholar] [CrossRef] [PubMed]
[35] Qamar, A., Libby, P. and Bhatt, D.L. (2019) Targeting RNA to Lower Triglycerides: Long Strides from Short Molecules. European Heart Journal, 40, 2797-2800. [Google Scholar] [CrossRef] [PubMed]
[36] Arca, M., Hsieh, A., Soran, H., et al. (2018) The Effect of Volanesorsen Treatment on the Burden Associated with Familial Chylomicronemia Syndrome: The Results of the ReFOCUS Study. Expert Review of Cardiovascular Therapy, 16, 537-546. [Google Scholar] [CrossRef] [PubMed]
[37] Witztum, J.L., Gaudet, D., Freedman, S.D., et al. (2019) Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. The New England Journal of Medicine, 381, 531-542. [Google Scholar] [CrossRef] 
[38] Li, J.-J., Ma, C.-S., Zhao, D., et al. (2022) Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement. JACC: Asia, 2, 653-665. [Google Scholar] [CrossRef] [PubMed]
[39] Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. [Google Scholar] [CrossRef] [PubMed]
[40] Yeang, C., Karwatowska-Prokopczuk, E., Su, F., et al. (2022) Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 79, 1035-1046. [Google Scholar] [CrossRef] [PubMed]

为你推荐